Study of effectiveness of the switch from Gn-RH agonist to degarelix for patients with prostate cancer as a second-line hormone therapy
Not Applicable
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000015300
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients 1)who have a treatment history of degarelix 2)who have a treatment history of Enzalutamide or Abraterone 3)who are using steroid 4)who are using estrogen 5)who are using 5-alpha-reductase inhibitor 6)who have a serious cardiovascular disease 7)who have in active cancer except prostate cancer 8)have an allergy to degarelix 9)who are disqualified by a doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA Responder rate at 12w
- Secondary Outcome Measures
Name Time Method 1)Time to PSA increase by 25 % compared to PSA st starting this study in Responder 2)Time to PSA progression survival 3)Time to treatoment fairule 4)Time to overall survival 5)Time to cancer specific survival 6)Time to radiographic PFS 7)safty